Advances in Migraine Therapy: A Comprehensive Review

Abstract

Background: Migraine is a prevalent and debilitating neurological disorder, affecting a significant portion of the global population, particularly women. Characterized by intense pulsating headaches, nausea, and sensory disturbances, migraines can significantly impair quality of life. Traditional treatments often offer suboptimal relief or cause undesirable side effects, necessitating the exploration of more effective and targeted therapies. Objective: The aim of this review is to comprehensively examine recent advances in both pharmacological and non-pharmacological approaches for the treatment and management of migraines, highlighting innovations such as CGRP inhibitors, Gepants, Ditans, neuromodulation techniques, and personalized medicine. Methods: This review synthesizes current scientific literature, clinical trial findings, and global prevalence data to evaluate emerging migraine therapies. It categorizes treatment strategies into symptomatic and preventive approaches and includes special considerations for children and women. Results: Recent advancements have led to the development of CGRP inhibitors (e.g., erenumab, fremanezumab), oral gepants (ubrogepant, rimegepant), and ditans (lasmiditan), which demonstrate improved efficacy and safety compared to conventional treatments. Non-pharmacological innovations, including neuromodulation devices (Cefaly, TMS), cognitive behavioral therapy, and botulinum toxin injections, offer effective alternatives, especially for patients with contraindications to medications. Personalized medicine and genetic profiling are also enhancing treatment precision. Conclusion: These innovations offer safer, more effective, and individualized options for migraine sufferers. Continued research and clinical validation are essential to further refine these therapies and improve long-term patient outcomes.